Journal Scans
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Cetuximab and First-Line Taxane/Carboplatin in Advanced NSCLC
TJ Lynch, T Patel, L Dreisbach, M McCleod, WJ Heim, RC Hermann, E Paschold, NO Iannotti, S Dakhil, S Gorton, V Pautret, MR Weber, D Woytowitz
Yes
20100120
2010 Feb 20
J Clin Oncol
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
J Clin Oncol. 2010 Feb 20;28(6):911-917, TJ Lynch, T Patel, L Dreisbach, M McCleod, WJ Heim, RC Hermann, E Paschold, NO Iannotti, S Dakhil, S Gorton, V Pautret, MR Weber, D Woytowitz
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Patients with advanced non–small-cell lung cancer (NSCLC) have poor survival outcomes. Standard first-line treatment for those patients with good performance status (PS) includes a platinum-containing doublet. In phase II studies of advanced NSCLC, the combination of cetuximab with platinum-based therapy was shown to be active. Results of the phase III FLEX trial demonstrated that the addition of cetuximab to vinorelbine and cisplatin significantly improved overall survival (OS). In this study, BMS099,...
